Sugawa M, Koide T, Naitoh S, Takato M, Matsui T, Asano T
Department of Pharmacology, Research Laboratories of Chugai Pharmaceutical Company Ltd., Komakado, Japan.
J Cereb Blood Flow Metab. 1991 Jan;11(1):135-42. doi: 10.1038/jcbfm.1991.16.
The pharmacological and biochemical mechanisms of contractile responses to the protein kinase C (PKC) activator phorbol-12,13-diacetate (PDA) were investigated in canine basilar arteries. In the normal medium, PDA elicited a strong, dose-related, and slow-developing sustained contraction. Among the constrictors examined, including serotonin, prostaglandin F2 alpha, and endothelin, only PDA yielded contractions in a Ca2(+)-free medium. In both media, the PDA-induced contractions were virtually inhibited by either staurosporine, H-7, or quinacrine, while neither neurotransmitter blockades nor R24571 (calmidazolium) exerted significant effects. In addition, it was shown that 8-bromocyclic GMP, but not 8-bromocyclic AMP, markedly curtailed the PDA-induced contractions. Biochemical analysis, furthermore, showed that PDA induced increased phosphorylations of 27- and 96-kDa and proteins other than the myosin light chain (MLC) 20-kDa protein. Thus, the present results open up a novel mechanism of sustained cerebral artery contractions, where PKC activation rather than Ca2+/calmodulin/MLC system plays a key role that is regulated both by phospholipase A2 and by cyclic GMP.
在犬基底动脉中研究了对蛋白激酶C(PKC)激活剂佛波醇-12,13-二乙酸酯(PDA)收缩反应的药理和生化机制。在正常培养基中,PDA引发强烈的、剂量相关的和缓慢发展的持续性收缩。在所检测的收缩剂中,包括5-羟色胺、前列腺素F2α和内皮素,只有PDA在无Ca2+的培养基中产生收缩。在两种培养基中,PDA诱导的收缩几乎都被星形孢菌素、H-7或奎纳克林抑制,而神经递质阻断剂和R24571(氯咪达唑)均未产生显著影响。此外,研究表明8-溴环鸟苷(8-bromocyclic GMP)而非8-溴环腺苷(8-bromocyclic AMP)能显著抑制PDA诱导的收缩。此外,生化分析表明,PDA诱导27 kDa和96 kDa蛋白以及肌球蛋白轻链(MLC)20 kDa蛋白以外的其他蛋白的磷酸化增加。因此,本研究结果揭示了一种持续性脑动脉收缩的新机制,其中PKC激活而非Ca2+/钙调蛋白/MLC系统起关键作用,且该作用受磷脂酶A2和环鸟苷的调控。